Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership
Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS).
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.
Alexandre Lebeaut, M.D., Executive Vice President, Research & Development and Chief Scientific Officer, Ipsen, commented, “We are very pleased to partner with the IACS at the MD Anderson Cancer Center whose reputation in scientific excellence and clinical care in Oncology is outstanding. Through this collaboration, we aim to synergize IACS’ scientific expertise with Ipsen’s drug development capabilities to deliver innovative therapies more rapidly to patients in need, and advance patient care in Oncology”
MD Anderson and Ipsen also will collaborate to conduct additional pre-clinical studies to further explore the potential of the drug candidate’s mode-of-action and expanded indications. The detailed financial terms of the agreement, including development and commercial milestones and royalties, have not been disclosed.
“We believe this partnership has the potential to deliver a new therapeutic option to our patients,” said Stephen Hahn, M.D., chief medical executive at MD Anderson. “This focus on accelerating the development of efficient treatments is vital to our mission of ending cancer and to providing the very best care we can to those who need it most.”
Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 49 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report's "Best Hospitals" survey. It has ranked as one of the nation's top two hospitals for cancer care since the survey began in 1990, and has ranked first 13 times in the last 16 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Ipsen Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2017 Registration Document available on its website (www.ipsen.com).
Ian Weatherhead, +44 (0) 1753 627733
Vice President, Corporate External Communications
Marisol Peron, Tel.: +1 908-275-6330
Vice President, NA Communications
Brigitte Le Guennec, +33 (0)1 58 33 51 17
Senior Manager, Global External Communications
Eugenia Litz, +44 (0) 1753 627721
Vice President, Investor Relations
Myriam Koutchinsky, +33 (0)1 58 33 51 04
Investor Relations Manager
Work : 713-745-1898
Email : firstname.lastname@example.org
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innovid Bolsters Omni-channel Advertising Offering With Acquisition of Herolens18.9.2019 10:30:00 CEST | Press release
Innovid, the only independent omni-channel advertising and analytics platform built for television, today announced the acquisition of Herolens, an international advertising software company with expertise in display creative optimization technology. The acquisition expands Innovid’s existing global ad serving, dynamic creative personalization, and advanced measurement capabilities to include display formats alongside the company’s award-winning TV, video, and social solutions. Herolens is the leading creative management platform headquartered in Latin America, focused on delivering data-driven, dynamic and personalized creative on behalf of brands such as Coke, Renault, and Mercado Libre. Known for their flexible self-service, hybrid and full-service models, clients use Herolens as a central hub for digital asset management and dynamic creative customization, as well as display ad serving. “We’ve heard first-hand from our clients, the world’s largest TV spenders, the need to leverage
Smiths Detection opens office at Imperial College London’s White City campus18.9.2019 10:00:00 CEST | Press release
Global threat detection and security technologies company, Smiths Detection today announces the opening of an office at Imperial College London’s White City Campus within the I-Hub, with the intention of establishing a research and development (R&D) partnership between the two organizations. Imperial’s co-working facility in the I-Hub provides a space for Smiths Detection’s scientists and engineers to work more closely with the Colleges network of academics and researchers on cutting edge technologies for the defence and security markets. Smiths Detection’s new office adds to Imperial’s larger initiative to create a hub that focuses on security research, innovation and engagement led by the Institute of Security Science and Technology (ISST). Smiths Detection will be sitting amongst other innovators in the field who have already established offices at White City, including Airbus, Saab and DASA. “Imperial are looking to bring together some of the top innovators in the field to help add
Biedermann Motech to Introduce MOSS VRS® - The Next Generation Pedicle Screw Technology™ to the US Market18.9.2019 10:00:00 CEST | Press release
Biedermann Motech, the company that developed the world’s first polyaxial pedicle screw (MOSS® System) and pioneer in the spinal market for more than 30 years, today announced the further expansion of its product portfolio of advanced solutions for spinal surgery with the introduction of the MOSS VRS® Pedicle Screw System at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, September 25-27, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190918005382/en/ Biedermann Motech to introduce MOSS VRS® - The Next Generation Pedicle Screw Technology™ to the US market at NASS 2019 in Chicago. Please join us at booth #2230 to learn more about the MOSS VRS System which allows the surgeon to lock the polyaxial angle of the pedicle screw at any angle, at any time during surgery, providing unmatched intraoperative options using a single, highly functional implant. (Photo: Business Wire) The MOSS VRS System feature
Thales Expands Advanced Access Management Capabilities for Authentication Customers to Take on Evolving Threat Landscape18.9.2019 09:56:00 CEST | Press release
From today, new adaptive authentication, single sign on and application visibility capabilities are available for Thales’ SafeNet Authentication Service customers with an automatic migration to SafeNet Trusted Access. With the enhanced access management capabilities of SafeNet Trusted Access, organizations have better control and visibility over their cloud estate with greater security, ease of use, and automated security capabilities to reduce the threats of identity-based attacks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190918005393/en/ (Photo: Thales) According to the 2019 Thales Access Management Index, the majority (97%) of IT leaders believe that cloud access management is necessary to continue their cloud adoption, and almost all (94%) have changed their security policies around access management due to a rise in security breaches in the last 12 months. With adaptive authentication and flexible access managemen
Janssen to Highlight Depth of Solid Tumour Portfolio with Multiple Data Presentations at ESMO 201918.9.2019 08:38:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology (ESMO) 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain. Among Janssen’s 12 accepted abstracts is an oral presentation reporting overall survival from the Phase 3 SPARTAN study investigating the use of apalutamide in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the Phase 3 TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrating maintenance of overall health-related quality of life with apalutamide; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects
Tradeweb Launches Electronic Multi-Asset Package Trading on its Interest Rate Swaps Platform18.9.2019 08:00:00 CEST | Press release
Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets, announced the launch of multi-asset package (MAP) trading on its global Interest Rate Swaps (IRS) platform. The first fully-electronic multi-asset package transaction using in-competition request-for-quote (RFQ) took place between Legal & General Investment Management (LGIM) and Bank of America Merrill Lynch. “Our MAP functionality is a clear demonstration of Tradeweb’s unique ability to enhance the trading experience for our clients, and connect the buy-side with deep liquidity pools across asset classes on a single electronic venue, and in this case a single trade,” said Lee Olesky, CEO of Tradeweb Markets. “Tradeweb’s strategic approach continues to be focused on building robust and efficient trading solutions that advance our markets globally.” The Tradeweb MAP functionality builds on the firm’s award-winning NPV (net present value) list trading to